Patents by Inventor Leigh T Canham

Leigh T Canham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180333509
    Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 22, 2018
    Inventors: Roger ASTON, Leigh T. CANHAM
  • Patent number: 9980911
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 29, 2018
    Assignee: PSIVIDA US, INC.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 9962396
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: May 8, 2018
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Patent number: 9808421
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: November 7, 2017
    Assignee: PSIVIDA US, INC.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20170128464
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention.
    Type: Application
    Filed: November 7, 2016
    Publication date: May 11, 2017
    Applicant: pSivida US. Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Patent number: 9603801
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 28, 2017
    Assignee: pSivida US, Inc.
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20170049703
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: April 29, 2016
    Publication date: February 23, 2017
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Patent number: 9566235
    Abstract: In some aspects, the invention relates to a porous implant, comprising a resorbable or bio-erodible porous silicon-based carrier material; a reservoir formed within the body of the porous silicon-based carrier material; and a beneficial substance disposed within the reservoir.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: February 14, 2017
    Assignee: pSiMedica Limited
    Inventors: Leigh T. Canham, Christopher P. Barrett, Timothy I. Cox, Peter J. Wright, Andrew P. Bowditch
  • Publication number: 20170035690
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20160367709
    Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.
    Type: Application
    Filed: September 2, 2016
    Publication date: December 22, 2016
    Inventors: Roger ASTON, Leigh T. CANHAM
  • Patent number: 9486459
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: November 8, 2016
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Publication number: 20160243276
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 25, 2016
    Inventors: Paul ASHTON, Leigh T. Canham, Christian Barnett
  • Patent number: 9333173
    Abstract: This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 10, 2016
    Assignee: pSivida US, Inc.
    Inventors: Paul Ashton, Leigh T. Canham, Christian Barnett
  • Publication number: 20160075776
    Abstract: This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The reservoir may be used in vitro or in vivo to maintain an equilibrium concentration of a therapeutic agent over an intended period of time such as over multiple days, weeks, months, or years. Additionally, the reservoir may be reloaded with additional therapeutic agent. These reservoirs may be used for treating or preventing conditions of a subject such as chronic diseases.
    Type: Application
    Filed: September 16, 2015
    Publication date: March 17, 2016
    Inventors: Paul Ashton, Hong Guo, Leigh T. Canham, Dinesh Nadarassan
  • Publication number: 20150352211
    Abstract: In some aspects, the invention relates to a porous implant, comprising a resorbable or bio-erodible porous silicon-based carrier material; a reservoir formed within the body of the porous silicon-based carrier material; and a beneficial substance disposed within the reservoir.
    Type: Application
    Filed: August 18, 2015
    Publication date: December 10, 2015
    Inventors: Leigh T. Canham, Christopher P. Barrett, Timothy I. Cox, Peter J. Wright, Andrew P. Bowditch
  • Patent number: 9205051
    Abstract: A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the beneficial substance in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-erodible doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: December 8, 2015
    Assignee: pSiMedica Limited, Inc.
    Inventors: Leigh T. Canham, Christopher P. Barrett, Timothy I. Cox, Peter J. Wright, Andrew P. Bowditch
  • Publication number: 20150272965
    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 1, 2015
    Inventors: Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
  • Publication number: 20140309610
    Abstract: This application provides a device for delivering a beneficial substance to a patient. The device comprises a shell enclosing a plurality of carrier particles. The carrier particles are porous, and a beneficial substance, such as a drug, is disposed in the pores. The drug can diffuse out of the pores, into the interior of the device, and then through at least one permeable portion of the shell. This application also provides methods of making and using these devices.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Applicant: pSivida Corp.
    Inventors: Leigh T. Canham, Hong Guo, Martin Nazzaro, Christian Barnett
  • Publication number: 20140271886
    Abstract: The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: pSivida Corp
    Inventors: Christian Barnett, Paul Ashton, Leigh T. Canham
  • Publication number: 20140193335
    Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: ENIGMA THERAPEUTICS LIMITED
    Inventors: Roger ASTON, Leigh T. CANHAM